Newer antidepressants and the cytochrome P450 system

Charles Nemeroff, C. Lindsay Devane, Bruce G. Pollock

Research output: Contribution to journalArticle

471 Citations (Scopus)

Abstract

Objective: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. Method: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. Results: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophrylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome, P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. Conclusions: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medications, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.

Original languageEnglish
Pages (from-to)311-320
Number of pages10
JournalAmerican Journal of Psychiatry
Volume153
Issue number3
StatePublished - Mar 1 1996
Externally publishedYes

Fingerprint

Cytochrome P-450 Enzyme System
Antidepressive Agents
Drug Interactions
Fluvoxamine
Sertraline
Fluoxetine
Astemizole
Terfenadine
Triazolam
Alprazolam
Nortriptyline
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6
Paroxetine
Desipramine
Clozapine
Carbamazepine
Phenytoin
Diazepam

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Nemeroff, C., Devane, C. L., & Pollock, B. G. (1996). Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153(3), 311-320.

Newer antidepressants and the cytochrome P450 system. / Nemeroff, Charles; Devane, C. Lindsay; Pollock, Bruce G.

In: American Journal of Psychiatry, Vol. 153, No. 3, 01.03.1996, p. 311-320.

Research output: Contribution to journalArticle

Nemeroff, C, Devane, CL & Pollock, BG 1996, 'Newer antidepressants and the cytochrome P450 system', American Journal of Psychiatry, vol. 153, no. 3, pp. 311-320.
Nemeroff, Charles ; Devane, C. Lindsay ; Pollock, Bruce G. / Newer antidepressants and the cytochrome P450 system. In: American Journal of Psychiatry. 1996 ; Vol. 153, No. 3. pp. 311-320.
@article{fa112d00bf9a4c049edacc34cfbc01f7,
title = "Newer antidepressants and the cytochrome P450 system",
abstract = "Objective: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. Method: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. Results: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophrylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome, P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. Conclusions: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medications, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.",
author = "Charles Nemeroff and Devane, {C. Lindsay} and Pollock, {Bruce G.}",
year = "1996",
month = "3",
day = "1",
language = "English",
volume = "153",
pages = "311--320",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Newer antidepressants and the cytochrome P450 system

AU - Nemeroff, Charles

AU - Devane, C. Lindsay

AU - Pollock, Bruce G.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Objective: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. Method: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. Results: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophrylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome, P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. Conclusions: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medications, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.

AB - Objective: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. Method: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. Results: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophrylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome, P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. Conclusions: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medications, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0029976064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029976064&partnerID=8YFLogxK

M3 - Article

C2 - 8610817

AN - SCOPUS:0029976064

VL - 153

SP - 311

EP - 320

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 3

ER -